Welcome to our dedicated page for enGene Therapeutics news (Ticker: ENGN), a resource for investors and traders seeking the latest updates and insights on enGene Therapeutics stock.
enGene Therapeutics Inc. develops non-viral genetic medicines for delivery to mucosal tissues and other organs. The company’s lead program is detalimogene voraplasmid, also known as detalimogene, for non-muscle invasive bladder cancer. Detalimogene is being evaluated in the multi-cohort LEGEND Phase 2 trial, including a pivotal cohort in high-risk, Bacillus Calmette-Guérin-unresponsive patients with carcinoma in situ, with or without concomitant papillary disease.
Recurring enGene news includes LEGEND clinical data, FDA designation and manufacturing-readiness updates, business and financial results, debt and equity financing activity, investor-conference participation, and corporate matters such as the completed name change from enGene Holdings Inc. to enGene Therapeutics Inc. The company’s common shares trade on Nasdaq under ENGN, and its listed warrants trade under ENGNW.
enGene (Nasdaq: ENGN) reported its Q2 2024 results, showing significant financial and strategic updates. The company has expanded its LEGEND study of EG-70 into high-risk papillary-only NMIBC and plans to release interim data by September 2024. enGene secured a $200 million private placement in February and has $264.8 million in cash as of April 2024, expected to fund operations into 2027. However, its net loss increased to $15.0 million from $6.5 million YoY due to rising operating expenses. Additionally, the company announced key leadership changes and the deprioritization of the EG-i08 program for cystic fibrosis.
enGene Holdings, a clinical-stage genetic medicines company, announced that their CEO, Jason Hanson, will present a corporate overview at the Jefferies Global Healthcare Conference.
The event will take place in New York City on June 5, 2024, at 12:30 p.m. ET.
enGene's lead program, EG-70, is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
The presentation will be webcast live and archived on the enGene website for 90 days.
enGene Holdings Inc. (Nasdaq: ENGN) announced an oral presentation at the American Urology Association 2024 Annual Meeting regarding its non-viral gene therapy EG-70 for BCG-unresponsive non-muscle invasive bladder cancer. The presentation highlights the rational design of EG-70 to address challenges faced by other treatment options. Promising Phase 1 data show complete response rates of 70% and 60% at three and six months, respectively, with encouraging safety results.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.